Key Development On September 3, 2026, the Ho Chi Minh City Department of Health announced a VND160 million administrative penalty... Read more
Category: Uncategorized
VIETNAM ENTERS THE LONG-TERM CARE ERA: LÁNG SEN MODEL HIGHLIGHTS THE INFRASTRUCTURE GAP BEHIND THE EMERGING SILVER ECONOMY
Key Development The launch of the Láng Sen Social Protection Facility for Older Persons in Can Tho represents more than... Read more
Healthcare System Decentralization & Primary Care Capacity: Vietnam Ministry of Health Outlines Multi-Pronged Reform Agenda – Enforcing 3-Tier Technical Classification, 2026–2030 Satellite Hospital Master Plan, and Standardized Medical Device Procurement
Key Development On the morning of September 3, 2026, the Ministry of Health (MOH) of Vietnam released a comprehensive policy... Read more
4 Reasons Why Changing A Diabetic Diet Is So Difficult
Dietary change is a cornerstone of effective diabetes management. Yet for many people, it is far from easy — our... Read more
Every Employee Can Become A “First Responder”
Safety is not one person's job — it is everyone's responsibility In any workplace, incidents can happen without warning: a... Read more
Workforce transformation in the AI era: Redesigning processes over role elimination
The illusion of efficiency and the cost of premature restructuring Many corporate layoff announcements currently framed around artificial intelligence reflect... Read more
The invisible class ceiling in compensation negotiations and career advancement
In conventional corporate compensation models, negotiation is widely celebrated as a meritocratic mechanism: employees articulate their value proposition, leadership conducts... Read more
Immunology M&A & Precision Autoimmunity: Eli Lilly to Acquire Merida Biosciences for Up to $2.88 Billion in Cash – Bolstering Thyroid Autoimmune Pipeline (MER511) to Diversify Beyond Incretin Blockbusters
Key Development On August 31, 2026, global pharmaceutical leader Eli Lilly and Company (NYSE: LLY) entered into a definitive acquisition... Read more
Next-Generation Vaccinology & In Silico mRNA Platforms: GSK Advances Dual-Antigen (HA + NA) mRNA Seasonal Influenza Candidate to Phase 3 Trials – Challenging Moderna Following Superior Immune Responses in Young and Older Adult Cohorts
Key Development On September 1, 2026, British biopharmaceutical leader GSK plc (LSE/NYSE: GSK) announced the advancement of its investigational mRNA-based... Read more









